Carbapenem-nonsusceptible Gram-negative pathogens in ICU and non-ICU settings in US hospitals in 2017: A multicenter study

Open Forum Infectious Diseases

Volumn 5, Issue 10, 2018, Pages

  McCann, Eilish ^a   Srinivasan, Arjun ^b   Andrew DeRyke, C ^a   Ye, Gang ^c   DePestel, Daryl D ^a   Murray, John ^c   Gupta, Vikas ^c  

^a MERCK RESEARCH LABORATORIES   (United States)

^b NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^c BD Technologies   (United States)

Author keywords

Carbapenems; Gram negative pathogens; Intensive care unit; Surveillance; Susceptibility

Indexed keywords

CARBAPENEM; DORIPENEM; ERTAPENEM; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM;

ACINETOBACTER; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL STEWARDSHIP; ARTICLE; BACTERIUM DETECTION; BACTERIUM ISOLATION; BLOOD SAMPLING; CARBAPENEM RESISTANT ACINETOBACTER BAUMANNII; CARBAPENEM RESISTANT PSEUDOMONAS AERUGINOSA; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; CITROBACTER FREUNDII; CROSS-SECTIONAL STUDY; ENTEROBACTER AEROGENES; ENTEROBACTER CLOACAE; ESCHERICHIA COLI; GEOGRAPHIC DISTRIBUTION; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; HEALTH CARE SYSTEM; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MORBIDITY; MORGANELLA MORGANII; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDY; SERRATIA MARCESCENS; UNITED STATES; URINE SAMPLING; WOUND;

EID: 85063693649     PISSN: None     EISSN: 23288957     Source Type: Journal    
DOI: 10.1093/ofid/ofy241     Document Type: Article

References (30)

1. Papp-Wallace KM, Endimiani A, Taracila MA, Bonomo RA. Carbapenems: past, present, and future. Antimicrob Agents Chemother 2011; 55:4943-60.
2. Bartsch SM, McKinnell JA, Mueller LE, et al. Potential economic burden of carbapenem-resistant Enterobacteriaceae (CRE) in the United States. Clin Microbiol Infect 2017; 23:48.39-48.e16.
3. Thaden JT, Pogue JM, Kaye KS. Role of newer and re-emerging older agents in the treatment of infections caused by carbapenem-resistant Enterobacteriaceae. Virulence 2017; 8:403-16.
4. Kollef MH, Bassetti M, Francois B, et al. The intensive care medicine research agenda on multidrug-resistant bacteria, antibiotics, and stewardship. Intensive Care Med 2017; 43:1187-97.
5. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. https://www.cdc.gov/drugresistance/biggest_threats.html. Accessed 1 December 2017.
6. World Health Organization. Global priority list of antibiotic-resistant bacteria to guide research, discover, and development of new antibiotics. 2017. http://apps.who.int/medicinedocs/documents/s23171en/s23171en.pdf. Accessed 5 May 2018.
7. Micek ST, Welch EC, Khan J, et al. Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to Gram-negative bacteria: a retrospective analysis. Antimicrob Agents Chemother 2010; 54:1742-8.
8. Brossette SE, Hacek DM, Gavin PJ, et al. A laboratory-based, hospital-wide, electronic marker for nosocomial infection: the future of infection control surveillance? Am J Clin Pathol 2006; 125:34-9.
9. Tabak YP, Zilberberg MD, Johannes RS, et al. Attributable burden of hospital-onset Clostridium difficile infection: a propensity score matching study. Infect Control Hosp Epidemiol 2013; 34:588-96.
10. Ridgway JP, Sun X, Tabak YP, et al. Performance characteristics and associated outcomes for an automated surveillance tool for bloodstream infection. Am J Infect Control 2016; 44:567-71.
11. Morrill HJ, Pogue JM, Kaye KS, LaPlante KL. Treatment options for carbapenem-resistant Enterobacteriaceae infections. Open Forum Infect Dis 2015; 2:ofv050.
12. Gupta N, Limbago BM, Patel JB, Kallen AJ. Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. Clin Infect Dis 2011; 53:60-7.
13. Bonomo RA, Burd EM, Conly J, et al. Carbapenemase-producing organisms: a global scourge. Clin Infect Dis 2018; 66:1290-7.
14. Zilberberg MD, Nathanson BH, Sulham K, et al. Carbapenem resistance, inappropriate empiric treatment and outcomes among patients hospitalized with Enterobacteriaceae urinary tract infection, pneumonia and sepsis. BMC Infect Dis 2017; 17:279.
15. Braykov NP, Eber MR, Klein EY, et al. Trends in resistance to carbapenems and third-generation cephalosporins among clinical isolates of Klebsiella pneumoniae in the United States, 1999-2010. Infect Control Hosp Epidemiol 2013; 34:259-68.
16. Wilson BM, El Chakhtoura NG, Patel S, et al. Carbapenem-resistant Enterobacter cloacae in patients from the US Veterans Health Administration, 2006-2015. Emerg Infect Dis 2017; 23:878-80.
17. Cai B, Echols R, Magee G, et al. Prevalence of carbapenem-resistant Gram-negative infections in the United States predominated by Acinetobacter baumannii and Pseudomonas aeruginosa. Open Forum Infect Dis 2017; 4:ofx176.
18. Zilberberg MD, Nathanson BH, Sulham K, et al. Multidrug resistance, inappropriate empiric therapy, and hospital mortality in Acinetobacter baumannii pneumonia and sepsis. Crit Care 2016; 20:221.
19. Liu Q, Li X, Li W, et al. Influence of carbapenem resistance on mortality of patients with Pseudomonas aeruginosa infection: a meta-analysis. Sci Rep 2015; 5:11715.
20. Lemos EV, de la Hoz FP, Einarson TR, et al. Carbapenem resistance and mortality in patients with Acinetobacter baumannii infection: systematic review and meta-analysis. Clin Microbiol Infect 2014; 20:416-23.
21. Hall MJ, Levant S, DeFrances CJ. Trends in inpatient hospital deaths: National Hospital Discharge Survey, 2000-2010. NHS Data Brief 2013; (118):1-8.
22. Kyaw MH, Kern DM, Zhou S, et al. Healthcare utilization and costs associated with S. aureus and P. aeruginosa pneumonia in the intensive care unit: a retrospective observational cohort study in a US claims database. BMC Health Serv Res 2015; 15:241.
23. Henig O, Cober E, Richter SS, et al. A prospective observational study of the epidemiology, management, and outcomes of skin and soft tissue infections due to carbapenem-resistant Enterobacteriaceae. Open Forum Infect Dis 2017; 4:ofx157.
24. Sader HS, Farrell DJ, Flamm RK, Jones RN. Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009-2011). Diagn Microbiol Infect Dis 2014; 78:443-8.
25. Sader HS, Castanheira M, Flamm RK, et al. Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia. Int J Antimicrob Agents 2015; 46:53-9.
26. Lodise T, Ye MJ, Zhao Q. Prevalence of invasive infections due to carbapenem-resistant Enterobacteriaceae among adult patients in U.S. hospitals. Antimicrob Agents Chemother 2017; 61:e00228-17.
27. van Loon K, Voor In't Holt AF, Vos MC. Systematic review and meta-analyses of the clinical epidemiology of carbapenem-resistant Enterobacteriaceae. Antimicrob Agents Chemother 2017; 62:e01730-17.
28. Armand-Lefèvre L, Angebault C, Barbier F, et al. Emergence of imipenem-resistant Gram-negative bacilli in intestinal flora of intensive care patients. Antimicrob Agents Chemother 2013; 57:1488-95.
29. MacVane SH. Antimicrobial resistance in the intensive care unit: a focus on gram-negative bacterial infections. J Intensive Care Med 2017; 32:25-37.
30. Shorr AF. Review of studies of the impact on Gram-negative bacterial resistance on outcomes in the intensive care unit. Crit Care Med 2009; 37:1463-9.